Artificial Intelligence (AI) has the potential to transform and significantly accelerate drug discovery, and so its integration has become a pivotal focus for pharmaceutical companies.
However, the scale and heritage of MidPharmas make it challenging to adapt to emerging technologies. They have limited financial and human resources, making acquisitions riskier and the integration of technology more difficult.
In this paper, we outline what MidPharmas should do about AI in drug discovery, highlighting the importance of:
- Building the right mindset
- Engaging in quality AI collaborations
- Adopting AI iteratively
MidPharmas that explore and/or embrace AI in drug discovery enhance their competitive position, by generating innovative drug candidates faster and cheaper than by traditional methods.
You can download your free copy of this report via the button above.
